Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Hematology

Hemophilia

Factor IX; factor Xa

In vitro and monkey studies identified a bifunctional antibody targeting factor IX and factor Xa that could help treat hemophilia A.
In human factor VIII-deficient plasma, an antibody that bound factor IX and factor Xa induced coagulation. In a monkey model of hemophilia A, the same antibody had high subcutaneous bioavailability and a long half-life and decreased bleeding compared with no treatment. Next steps include clinical testing.
At least 10 companies have therapeutics targeting factor VIII to treat hemophilia in development stages ranging from clinical to marketed.

SciBX 5(40); doi:10.1038/scibx.2012.1053
Published online Oct. 11, 2012

Findings patented; licensing status undisclosed

Kitazawa, T. et al. Nat. Med.; published online Sept. 30, 2012;
doi:10.1038/nm.2942
Contact: Takehisa Kitazawa,
Fuji-Gotemba Research Laboratories, Shizuoka, Japan
e-mail:
kitazawatkh@chugai-pharm.co.jp